Thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
The US initially seemed to follow containment, only pushing back North Korea across the 38th Parallel and restoring South Korea's sovereignty while allowing North Korea's survival as a state. However, the success of the Inchon landing inspired the US/UN forces to pursue a rollback strategy instead and to overthrow communist North Korea, thereby allowing nationwide elections under UN auspices. General Douglas MacArthur then advanced into North Korea. The Chinese, fearful of a possible US invasion, sent in a large army and pushed the UN forces back below the 38th parallel. The episode was used to support the wisdom of the containment doctrine as opposed to rollback. The Communists were later pushed to roughly around the original border, with minimal changes. Among other effects, the Korean War galvanised NATO to develop a military structure. The Korean Armistice Agreement was approved in July 1953.
Beriglobin P, human hepatitis A immunoglobulin, liquid 16% solution for intramuscular injection Berirab P, human rabies immunoglobulin, liquid 16% solution for intramuscular injection Carimune NF, Sandoglobulin, Sanglopor human normal immunoglobulin, freeze-dried formulations for intravenous administration Cytogam, human cytomegalovirus immunoglobulin. Liquid immunoglobulin containing a standardized amount of antibody to cytomegalovirus. Hepatitis B Immunoglobulin P Behring, human hepatitis B immunoglobulin, liquid 16% solution for intramuscular injection Hizentra, Human normal immunoglobulin. Liquid 20% immunoglobulin solution, ready-to-use for subcutaneous administration Privigen, human polyvalent immunoglobulin, liquid 10% solution for intravenous injection Rhesogamma P, human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection. Rhophylac human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection. Sandoglobulin NF Liquid, Redimune, Redimune NF Liquid, human normal immunoglobulin, liquid 12% solution for intravenous administration Tetagam P, human tetanus immunoglobulin, liquid 16% solution for intramuscular injection Varicellon P, human varicella immunoglobulin, liquid 16% solution for intramuscular injection Vivaglobin, human normal immunoglobulin, liquid 16% solution for subcutaneous administration Coagulation/Bleeding Disorders:
{\displaystyle k_{1}\cdot (PA)^{t}+k_{2}\cdot (PB)^{t}+k_{3}\cdot (PC)^{t}\geq 2{\sqrt {k_{1}k_{2}k_{3}}}\left({\frac {(PD)^{t}}{\sqrt {k_{1}}}}+{\frac {(PE)^{t}}{\sqrt {k_{2}}}}+{\frac {(PF)^{t}}{\sqrt {k_{3}}}}\right).}
ribonuclease (RNase) Any of a class of nuclease enzymes which catalyze the hydrolytic cleavage of phosphodiester bonds in RNA molecules, thus severing polymeric strands of ribonucleotides into smaller components. Compare deoxyribonuclease.
Sources: en.wikipedia.org
Under the new Soviet designation, anyone from the former Cossack territories of the North Caucasus provided they were not Circassians or other ethnic minorities, could claim Cossack status. In World War II, during the German invasion of the Soviet Union, many Cossacks continued to serve in the Red Army. Some fought as cavalry in the Cossack divisions, such as the 17th Kuban Cossack Cavalry Corps and the famous Lev Dovator Corps, later awarded the honorific designation "guard" in recognition of its performance. Other Cossacks fought as partisans, although the partisan movement did not acquire significant traction during the German occupation of the traditional Cossack homelands in the North Caucasus. The 4th Guards Cossacks Cavalry Corps took part in the Moscow Victory Parade of 1945 on Red Square.
=== Patterns === In TCM, "pattern" (证; zhèng) refers to a "pattern of disharmony" or "functional disturbance" within the functional entities of which the TCM model of the body is composed. There are disharmony patterns of qi, xuě, the body fluids, the zàng-fǔ, and the meridians. They are ultimately defined by their symptoms and signs (i.e., for example, pulse and tongue findings). In clinical practice, the identified pattern usually involves a combination of affected entities (compare with typical examples of patterns). The concrete pattern identified should account for all the symptoms a person has.
Christianity, bolstered by Constantine's support, began shaping all aspects of life in the early Byzantine Empire. Despite the transition, the historian Anthony Kaldellis views Christianity as "bringing no economic, social, or political changes to the state other than being more deeply integrated into it". When the Roman state in the West collapsed politically, cultural differences began to divide the Christian churches of the East and West. Internal disputes within the Eastern churches led to the migration of monastic communities to Rome, exacerbating tensions between Rome and Constantinople. These disputes, particularly in Egypt and the eastern Mediterranean, eventually split the church into three branches: Chalcedonian, Monophysite (Coptic), and Nestorian. The Chalcedonian group maintained dominance within the empire's territories, while the Monophysite and Nestorian branches largely fell under Muslim rule in the 7th century. Eastern patriarchs frequently sought the Papacy's mediation in doctrinal and practical matters, but the pope's authority was not universally acknowledged, even in nearby regions like Northern Italy. By 600, the Slavic settlement of the Balkans disrupted communication between Rome and Constantinople, further widening the divide. The Arab and Lombard invasions, and the increased Frankish presence, deepened this estrangement and intensified disputes over jurisdiction and authority between the two spiritual centres.
Sources: en.wikipedia.org
==== Positive ion formation ==== Once the metastable carrier gas atoms (M*) released from the source, they initiate Penning ionization of nitrogen, atmospheric water and other gaseous species. Although some compounds can be ionized directly by Penning ionization, the most common positive-ion formation mechanism for DART involves ionization of atmospheric water.
The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy. In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.
The most common wild yeasts found in the vineyard are from the genera Kloeckera, Candida and Pichia with the species Kloeckera apiculata being the most dominant species by far. Saccharomyces cerevisiae, itself, is actually quite rarely found in the vineyard or on the surface freshly harvested wine grapes unless the winery frequently reintroduced winery waste (such as lees and pomace) into the vineyard. Recent research has shown how climate change is starting to affect yeast behavior during fermentation. Due to rising temperatures, grapes are arriving at wineries with higher sugar levels. This puts more stress on yeast and increases the risk of stuck fermentations. Because of this, winemakers are starting to pay closer attention to what yeast they choose for fermentation more than ever before. Mixed fermentations, which use non-Saccharomyces yeasts alongside Saccharomyces cerevisiae, are also becoming increasingly popular to help enhance wine complexity and reduce volatile acidity. Unlike the "ambient" Saccharomyces wild yeast, these genera of wild yeasts have very low tolerance to both alcohol and sulfur dioxide. They are capable of starting a fermentation and often begin this process as early as the harvest bin when clusters of grapes get slightly crushed under their own weight. Some winemakers will try to "knock out" these yeasts with doses of sulfur dioxide, most often at the crusher before the grapes are pressed or allowed to macerate with skin contact.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.